BridgeBio Pharma Inc.
Income Statement
| Line Item | FY2018 | FY2017 |
|---|---|---|
| Revenue | — | — |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $140.1M | $30.6M |
| SG&A Expense | $43.6M | $13.3M |
| Operating Income | $-183.7M | $-43.9M |
| Operating Margin | — | — |
| Interest Expense | $2.5M | $13.0K |
| Pretax Income | $169.5M | $43.8M |
| Income Tax Expense | — | — |
| Net Income | $-169.5M | $-43.8M |
| Net Margin | — | — |
| EPS (Basic) | $-2.12 | $-1.00 |
| EPS (Diluted) | $-2.12 | $-1.00 |
| Shares Outstanding (Basic) | 92.1M | — |
| Shares Outstanding (Diluted) | 92.1M | — |
| Dividends Per Share | — | — |